A mid-cap biotech is weeks away from a Phase 3 readout that could reset the thesis.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

October 22, 2026   |   Read online     Unsubscribe     Sponsored by A Depression Drug Maker With a Phase 3 Readout Weeks Away A CNS-focused drug maker trades nearly 40% below its 52-week high, with a Phase 3 binge eating disorder readout guided for this quarter. The market has written it off as a launch that stalled. The pipeline tells a very different story. Finally, a Monday that doesn’t feel like one. Imagine a Saturday where you're not catching up on the CRM you didn't touch all week.  HubSpot's new self-updating CRM doesn't wait for you to log back in. Friday's calls are already logged. The deal that needs a nudge Monday morning is already flagged. The automation you set up once keeps running without you thinking about it. None of it needed you over the weekend.  Customers are already seeing it pay off: 45% more deals closed. Finally, you start Monday caught up, not behind. Get a Demo Axsome Therapeutics October 22 – Pre‑market Ticker: AXSM | Sector: Healthcare (Biotech) | Market Cap: $8.19B 30‑Second Take Axsome already sells three CNS drugs: Auvelity for depression (and, since April, for agitation in Alzheimer's dementia), Sunosi for excessive daytime sleepiness, and Symbravo for migraine. The near-term swing factor is the ENGAGE Phase 3 trial of Sunosi (solriamfetol) in binge eating disorder, with topline results guided for the fourth quarter of 2026. That means it could land any week now. Behind it sits a May 1, 2027 PDUFA date for AXS-12 in cataplexy in narcolepsy. The stock has slid hard from its 52-week high as the Alzheimer's agitation launch ramped slower than the Street hoped. You're buying a CNS growth story at a reset price, right before the catalysts hit. Trade Setup Timeframe: 4 to 12 weeks Edge type: Binary catalyst into oversold setup The thesis is a classic pre-readout setup. AXSM fell for 12 straight sessions into mid-October as RBC and Deutsche Bank trimmed price targets, so expectations are reset. ENGAGE is a true binary event. A positive result gives Sunosi a second major indication in a market with essentially one approved drug. A failure gets ugly fast. Size this like a biotech catalyst trade, not a core holding. You want exposure, not a bet-the-house position. Leave Granola and get up to 12 months free of Wispr Flow Notetaker + Dictation If you have paid time left on an individual Granola plan, we'll match it with a Wispr Flow subscription that includes Notetaker and dictation, and add bonus time, up to 12 months total. Sign in or create a Wispr account and submit proof of your plan to check eligibility. Try Notetaker Free Would you rather max out a Roth IRA every year starting at age 22, or wait until 35 but contribute double each year after that? Start small at 22 Start double at 35 Neither -- max out a traditional IRA instead of a Roth either way Start at 22, but only at half the annual contribution Snapshot Table Metric Value Current Stance Price $156.31 39% below 52-wk high 52‑week range $123.50 - $260.19 Lower third of range Market Cap $8.19B Mid-cap biotech P/E Ratio N/A Not applicable (pre-profitability) Beta 0.86 Moderate market sensitivity Avg Daily Volume 823.64K Calmer than the mid-October selloff Next Catalyst Phase 3 ENGAGE topline (solriamfetol in binge eating disorder), guided for Q4 2026 Imminent Chart 1-Month Trading Summary AXSM lost about 22% over the past month, sliding from around $205 in late September into the high $150s. That included 12 straight down sessions into mid-October and a 6% drop on October 13 as price-target cuts piled up. It has steadied in the mid-to-high $150s since, with volume cooling off from the selloff days. The good news if you're a buyer: expectations are reset, and the ENGAGE readout window is now open. Bull Case  Why It Works The real asset here is the pipeline layered on a growing commercial base. Product revenue rose 46% year over year in the second quarter to roughly $218 million, led by Auvelity. ENGAGE tests Sunosi, a drug Axsome already sells, in a brand-new indication. You're paying for the commercial business and getting a second shot on goal for free. The Catalysts ENGAGE is the near-term swing factor. The trial tests two doses of Sunosi (solriamfetol) against placebo over 12 weeks in adults with binge eating disorder, a condition with essentially one FDA-approved drug today. Positive data would hand Axsome a second major indication for a drug it already sells, meaning no new sales force needed. You just expand the label. The cataplexy in narcolepsy opportunity gets less airtime, but it matters. The FDA accepted the AXS-12 NDA in July, set a PDUFA target action date of May 1, 2027, and said it does not currently plan an advisory committee. That's your second shot on goal in the next seven months. If Axsome lands both a positive ENGAGE readout and AXS-12 approval, you're looking at a very different company by mid-2027. What The Numbers Say At roughly an $8.4B market cap, you're not paying mega-cap biotech premiums for a company with growing product revenue and two late-stage catalysts inside seven months. The stock sits nearly 40% below its 52-week high, while Wall Street targets still sit far above it (Needham reiterated Buy with a $268 target on October 15). The setup rewards you for being early. Bear Case  What Could Break It Biotech binary trades cut both ways. If ENGAGE misses on efficacy or throws up a safety signal, this stock loses 30% to 40% in a day. That's the honest downside you need to accept before putting money to work. The commercial Auvelity story has issues too. Scripts have been growing, but the Alzheimer's agitation ramp has been slower than bulls modeled, which is a big part of why the stock gave back so much from the highs. Payer pushback and prior authorization headaches are real for CNS launches. If management can't accelerate the trajectory, your "one Phase 3 readout away" thesis gets harder to sustain. The Valuation Risk Competition is another overhang. The depression market is crowded, and binge eating disorder has at least one established player with brand loyalty. Even positive data doesn't guarantee commercial success. You still need a differentiated label and reimbursement, and the current $8.36B cap already bakes in meaningful optionality. How To Size It Axsome burns cash building the commercial organization and running trials. If any of the near-term catalysts disappoint, raising money gets more expensive and more dilutive. Keep an eye on the next quarterly cash balance. Size this like a catalyst trade, not a core position. A failed readout can erase a year of patience in a single session. Quick Checklist  ✅ Thesis still valid after the latest close ✅ Volume confirms setup above $155 support ✅ Catalyst date confirmed: ENGAGE Phase 3 topline guided for Q4 2026 Deep‑Dive Links Latest earnings report Analyst ratings and price targets Short interest data Company profile and investor relations That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned! Best Regards, —Noah Zelvis Everyday Alpha   Elite Trade Club sends trending stocks and market-moving news straight to your cell, every session, before the opening bell. No app to download, no login, nothing to check. Just the names that are moving and the reason they're moving, while there's still a premarket to act in. 👉 Click here to get Elite Trade Club alerts on your cell for free P.S. It's 100% free, and you can stop at any time by replying STOP. Everyday Alpha is a publication of Elite Trade Media LLC. Disclosure: Content is for informational and entertainment purposes only and is not investment advice. Do not base investment decisions on this newsletter. Securities mentioned may be owned by our owners or operators, which could affect our objectivity. Consult a licensed financial advisor before making any investment decision. We may receive compensation from advertisers and affiliate links in this email, including for featured third-party offers. Everyday Alpha and its parent company are not registered investment advisors, broker-dealers, or financial planners. Nothing published by Everyday Alpha — including but not limited to newsletters, emails, text messages, social media posts, or website content — constitutes personalized investment advice, a recommendation to buy or sell any security, or an offer or solicitation to purchase or sell any financial instrument. All content is provided strictly for informational and educational purposes. You should not rely on any content published by Everyday Alpha as a substitute for professional financial, legal, or tax advice tailored to your individual circumstances. Always consult a qualified, licensed financial advisor before making any investment decision. Forward-Looking Statements: Content may contain forward-looking statements, including projections, opinions, and expectations regarding future events or financial performance. These statements are based on current information and assumptions at the time of writing and are inherently uncertain. Actual results may differ materially. Everyday Alpha is under no obligation to update or revise any forward-looking statement after publication. No Guarantee of Accuracy: While Everyday Alpha strives for accuracy, we make no representation or warranty — express or implied — regarding the completeness, reliability, or timeliness of any information provided. Errors, omissions, and outdated information may occur. All content is provided "as is" without warranty of any kind. Past Performance: Any reference to past performance of a security, strategy, or index is not indicative of future results. All investments carry risk, including the potential loss of principal. You could lose some or all of your invested capital. Editorial Process Disclosure: Everyday Alpha uses proprietary research tools, including AI, in its editorial process. All content is reviewed and approved by our editorial team before publication. Readers should independently verify any information before making financial decisions. Advertising & Affiliate Disclosure: Everyday Alpha receives compensation from third-party advertisers and may include paid promotions, sponsored content, and affiliate links within its publications. When you click on certain links or sign up for third-party services featured in our content, we may receive a commission or flat fee. This compensation may influence which companies or products are covered and how they are presented, though it does not affect our editorial opinions. Sponsored content is provided by advertisers and does not represent the views of Everyday Alpha. Conflicts of Interest: Contributors, editors, and affiliates of Everyday Alpha may hold positions in securities discussed in our content. These positions may be established or liquidated at any time without notice to readers. Limitation of Liability: Under no circumstances shall Everyday Alpha, its owners, employees, affiliates, or contributors be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of or reliance on any content published by Everyday Alpha. By reading, subscribing to, or otherwise engaging with Everyday Alpha content, you acknowledge and agree to the terms above. This email was sent via the beehiiv platform on behalf of Elite Trade Media LLC. Privacy Policy | Terms of Service Update your email preferences or unsubscribe here © 2026 Elite Trade Media LLC 1032 E Brandon Blvd #9644 Brandon, FL 33511, United States